Pat Cotroneo

2019

In 2019, Pat Cotroneo earned a total compensation of $4.3M as Chief Financial Officer at FibroGen, a 21% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$264,600
Option Awards$1,769,851
Salary$490,000
Stock Awards$1,782,963
Other$18,972
Total$4,326,386

Cotroneo received $1.8M in stock awards, accounting for 41% of the total pay in 2019.

Cotroneo also received $264.6K in non-equity incentive plan, $1.8M in option awards, $490K in salary and $19K in other compensation.

Rankings

In 2019, Pat Cotroneo's compensation ranked 2,685th out of 13,971 executives tracked by ExecPay. In other words, Cotroneo earned more than 80.8% of executives.

ClassificationRankingPercentile
All
2,685
out of 13,971
81st
Division
Manufacturing
967
out of 5,701
83rd
Major group
Chemicals And Allied Products
316
out of 2,200
86th
Industry group
Drugs
257
out of 1,886
86th
Industry
Pharmaceutical Preparations
190
out of 1,398
86th
Source: SEC filing on April 23, 2020.

Cotroneo's colleagues

We found five more compensation records of executives who worked with Pat Cotroneo at FibroGen in 2019.

2019

Thomas Neff

FibroGen

Chief Executive Officer

2019

K Yu

FibroGen

Chief Medical Officer

2019

James Schoeneck

FibroGen

Chief Executive Officer

2019

Elias Kouchakji

FibroGen

Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance

2019

Christine Chung

FibroGen

Senior Vice President, China Operations

News

You may also like